• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用双连接酶招募通过异三价靶向嵌合体增强蛋白质降解。

Leveraging Dual-Ligase Recruitment to Enhance Protein Degradation via a Heterotrivalent Proteolysis Targeting Chimera.

作者信息

Bond Adam G, Muñoz I Ordoño Miquel, Bisbach Celia M, Craigon Conner, Makukhin Nikolai, Caine Elizabeth A, Nagala Manjula, Urh Marjeta, Winter Georg E, Riching Kristin M, Ciulli Alessio

机构信息

Centre for Targeted Protein Degradation, School of Life Sciences, University of Dundee, 1 James Lindsay Place, Dundee DD1 5JJ, U.K.

CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences Vienna 1090, Austria.

出版信息

J Am Chem Soc. 2024 Dec 11;146(49):33675-33711. doi: 10.1021/jacs.4c11556. Epub 2024 Nov 28.

DOI:10.1021/jacs.4c11556
PMID:39606859
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11638965/
Abstract

Proteolysis targeting chimera (PROTAC) degraders are typically bifunctional with one E3 ligase ligand connected to one target protein ligand via a linker. While augmented valency has been shown with trivalent PROTACs targeting two binding sites within a given target protein, or used to recruit two different targets, the possibility of recruiting two different E3 ligases within the same compound has not been demonstrated. Here we present dual-ligase recruitment as a strategy to enhance targeted protein degradation. We designed heterotrivalent PROTACs composed of CRBN, VHL and BET targeting ligands, separately tethered via a branched trifunctional linker. Structure-activity relationships of 12 analogues qualifies AB3067 as the most potent and fastest degrader of BET proteins, with minimal E3 ligase cross-degradation. Comparative kinetic analyses in wild-type and ligase single and double knockout cell lines revealed that protein ubiquitination and degradation induced by AB3067 was contributed to by both CRBN and VHL in an additive fashion. We further expand the scope of the dual-ligase approach by developing a heterotrivalent CRBN/VHL-based BromoTag degrader and a tetravalent PROTAC comprising of two BET ligand moieties. In summary, we provide proof-of-concept for dual-E3 ligase recruitment as a strategy to boost degradation fitness by recruiting two E3 ligases with a single degrader molecule. This approach could potentially delay the outset of resistance mechanisms involving loss of E3 ligase functionality.

摘要

蛋白酶靶向嵌合体(PROTAC)降解剂通常是双功能的,一个E3连接酶配体通过一个连接子与一个靶蛋白配体相连。虽然已经证明,三价PROTAC靶向给定靶蛋白内的两个结合位点或用于招募两个不同的靶标时,可以增加价态,但尚未证明在同一化合物中招募两个不同E3连接酶的可能性。在此,我们提出双连接酶招募作为一种增强靶向蛋白降解的策略。我们设计了由CRBN、VHL和BET靶向配体组成的异三价PROTAC,它们通过一个分支三功能连接子分别连接。12种类似物的构效关系表明AB3067是最有效、降解BET蛋白最快的降解剂,且E3连接酶交叉降解最小。在野生型、连接酶单敲除和双敲除细胞系中的比较动力学分析表明,AB3067诱导的蛋白泛素化和降解是由CRBN和VHL以累加方式促成的。我们通过开发一种基于CRBN/VHL的异三价BromoTag降解剂和一种包含两个BET配体部分的四价PROTAC,进一步扩大了双连接酶方法的范围。总之,我们为双E3连接酶招募提供了概念验证,这是一种通过用单个降解剂分子招募两个E3连接酶来提高降解适应性的策略。这种方法可能会延迟涉及E3连接酶功能丧失的抗性机制的出现。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb84/11638965/f095ca54dabc/ja4c11556_0012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb84/11638965/1c646c523191/ja4c11556_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb84/11638965/8e63fe3f613c/ja4c11556_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb84/11638965/c651de281a2c/ja4c11556_0013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb84/11638965/ef9dd365f495/ja4c11556_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb84/11638965/1c3cf9fdb39c/ja4c11556_0014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb84/11638965/30baf6980921/ja4c11556_0015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb84/11638965/ef0de1ea042c/ja4c11556_0016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb84/11638965/767a03b30af2/ja4c11556_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb84/11638965/005d532f9678/ja4c11556_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb84/11638965/5abbacf041b8/ja4c11556_0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb84/11638965/4ce2a329f6eb/ja4c11556_0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb84/11638965/2734d4035b9d/ja4c11556_0017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb84/11638965/aebc8e1b0830/ja4c11556_0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb84/11638965/f20def0b2985/ja4c11556_0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb84/11638965/ad0613853b38/ja4c11556_0018.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb84/11638965/c5de075678d6/ja4c11556_0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb84/11638965/a7384a55cb74/ja4c11556_0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb84/11638965/f7fc526a84dd/ja4c11556_0019.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb84/11638965/f095ca54dabc/ja4c11556_0012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb84/11638965/1c646c523191/ja4c11556_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb84/11638965/8e63fe3f613c/ja4c11556_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb84/11638965/c651de281a2c/ja4c11556_0013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb84/11638965/ef9dd365f495/ja4c11556_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb84/11638965/1c3cf9fdb39c/ja4c11556_0014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb84/11638965/30baf6980921/ja4c11556_0015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb84/11638965/ef0de1ea042c/ja4c11556_0016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb84/11638965/767a03b30af2/ja4c11556_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb84/11638965/005d532f9678/ja4c11556_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb84/11638965/5abbacf041b8/ja4c11556_0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb84/11638965/4ce2a329f6eb/ja4c11556_0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb84/11638965/2734d4035b9d/ja4c11556_0017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb84/11638965/aebc8e1b0830/ja4c11556_0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb84/11638965/f20def0b2985/ja4c11556_0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb84/11638965/ad0613853b38/ja4c11556_0018.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb84/11638965/c5de075678d6/ja4c11556_0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb84/11638965/a7384a55cb74/ja4c11556_0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb84/11638965/f7fc526a84dd/ja4c11556_0019.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb84/11638965/f095ca54dabc/ja4c11556_0012.jpg

相似文献

1
Leveraging Dual-Ligase Recruitment to Enhance Protein Degradation via a Heterotrivalent Proteolysis Targeting Chimera.利用双连接酶招募通过异三价靶向嵌合体增强蛋白质降解。
J Am Chem Soc. 2024 Dec 11;146(49):33675-33711. doi: 10.1021/jacs.4c11556. Epub 2024 Nov 28.
2
Cereblon versus VHL: Hijacking E3 ligases against each other using PROTACs. cereblon 与 vhl :使用 protacs 相互劫持 e3 连接酶。
Bioorg Med Chem. 2019 Jun 15;27(12):2466-2479. doi: 10.1016/j.bmc.2019.02.048. Epub 2019 Feb 22.
3
E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones.E3 连接酶配体用于 PROTACs:它们是如何被发现的,以及如何发现新的配体。
SLAS Discov. 2021 Apr;26(4):484-502. doi: 10.1177/2472555220965528. Epub 2020 Nov 3.
4
Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders.VHL E3 连接酶在 PROTACs 设计中的旅程:从 VHL 配体到基于 VHL 的降解剂。
Eur J Med Chem. 2024 Feb 5;265:116041. doi: 10.1016/j.ejmech.2023.116041. Epub 2023 Dec 14.
5
PROTAC-mediated crosstalk between E3 ligases.PROTAC 介导的 E3 连接酶串扰。
Chem Commun (Camb). 2019 Feb 5;55(12):1821-1824. doi: 10.1039/c8cc09541h.
6
Workflow for E3 Ligase Ligand Validation for PROTAC Development.用于PROTAC开发的E3连接酶配体验证工作流程。
ACS Chem Biol. 2025 Feb 21;20(2):507-521. doi: 10.1021/acschembio.4c00812. Epub 2025 Feb 11.
7
Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation.同源PROTACs:VHL E3泛素连接酶的二价小分子二聚体,用于诱导自我降解。
Nat Commun. 2017 Oct 10;8(1):830. doi: 10.1038/s41467-017-00954-1.
8
Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders.小分子配体对 von Hippel-Lindau (VHL) E3 连接酶的发现及其作为抑制剂和 PROTAC 降解剂的应用。
Chem Soc Rev. 2022 Oct 3;51(19):8216-8257. doi: 10.1039/d2cs00387b.
9
Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase.募集的 E3 连接酶的取向决定了差异化 PROTAC 底物特异性。
Nat Commun. 2019 Jan 10;10(1):131. doi: 10.1038/s41467-018-08027-7.
10
Development of a versatile system for evaluating the target protein degradation activity of novel ubiquitin ligases utilizing existing PROTACs.利用现有PROTAC开发一种用于评估新型泛素连接酶的靶蛋白降解活性的通用系统。
Biochem Biophys Res Commun. 2025 Feb 16;749:151370. doi: 10.1016/j.bbrc.2025.151370. Epub 2025 Jan 20.

引用本文的文献

1
Advancing Design Strategy of PROTACs for Cancer Therapy.用于癌症治疗的PROTACs的先进设计策略
MedComm (2020). 2025 Jun 25;6(7):e70258. doi: 10.1002/mco2.70258. eCollection 2025 Jul.
2
Cellular parameters shaping pathways of targeted protein degradation.塑造靶向蛋白质降解途径的细胞参数。
Commun Biol. 2025 May 2;8(1):691. doi: 10.1038/s42003-025-08104-w.
3
Targeted protein degradation for cancer therapy.用于癌症治疗的靶向蛋白质降解

本文引用的文献

1
The rise of degrader drugs.降解药物的兴起。
Cell Chem Biol. 2023 Aug 17;30(8):864-878. doi: 10.1016/j.chembiol.2023.06.020. Epub 2023 Jul 25.
2
Functional E3 ligase hotspots and resistance mechanisms to small-molecule degraders.功能 E3 连接酶热点和小分子降解剂的耐药机制。
Nat Chem Biol. 2023 Mar;19(3):323-333. doi: 10.1038/s41589-022-01177-2. Epub 2022 Nov 3.
3
Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One.用第二种模式丰富蛋白水解靶向嵌合体:二比一更好。
Nat Rev Cancer. 2025 Apr 25. doi: 10.1038/s41568-025-00817-8.
4
Recommended Tool Compounds: Thienotriazolodiazepines-Derivatized Chemical Probes to Target BET Bromodomains.推荐的工具化合物:靶向BET溴结构域的噻吩并三唑二氮杂卓衍生化学探针。
ACS Pharmacol Transl Sci. 2025 Mar 14;8(4):978-1012. doi: 10.1021/acsptsci.4c00726. eCollection 2025 Apr 11.
5
Rational Design of PROTAC Linkers Featuring Ferrocene as a Molecular Hinge to Enable Dynamic Conformational Changes.以二茂铁为分子铰链实现动态构象变化的PROTAC连接子的合理设计。
J Am Chem Soc. 2025 Apr 23;147(16):13328-13344. doi: 10.1021/jacs.4c18354. Epub 2025 Apr 10.
6
Use of Aldehyde-Alkyne-Amine Couplings to Generate Medicinal Chemistry-Relevant Linkers.利用醛-炔-胺偶联反应生成与药物化学相关的连接子。
ACS Med Chem Lett. 2025 Jan 25;16(2):278-284. doi: 10.1021/acsmedchemlett.4c00531. eCollection 2025 Feb 13.
J Med Chem. 2022 Jul 28;65(14):9507-9530. doi: 10.1021/acs.jmedchem.2c00302. Epub 2022 Jul 11.
4
Driving E3 Ligase Substrate Specificity for Targeted Protein Degradation: Lessons from Nature and the Laboratory.靶向蛋白降解的 E3 连接酶底物特异性的驱动因素:来自自然界和实验室的经验教训。
Annu Rev Biochem. 2022 Jun 21;91:295-319. doi: 10.1146/annurev-biochem-032620-104421. Epub 2022 Mar 23.
5
PROTAC targeted protein degraders: the past is prologue.PROTAC 靶向蛋白降解剂:过去是序幕。
Nat Rev Drug Discov. 2022 Mar;21(3):181-200. doi: 10.1038/s41573-021-00371-6. Epub 2022 Jan 18.
6
Amide-to-Ester Substitution as a Strategy for Optimizing PROTAC Permeability and Cellular Activity.酰胺到酯的取代作为优化 PROTAC 通透性和细胞活性的策略。
J Med Chem. 2021 Dec 23;64(24):18082-18101. doi: 10.1021/acs.jmedchem.1c01496. Epub 2021 Dec 9.
7
Trivalent PROTACs enhance protein degradation via combined avidity and cooperativity.三价 PROTACs 通过结合亲和力和协同性增强蛋白质降解。
Nat Chem Biol. 2021 Nov;17(11):1157-1167. doi: 10.1038/s41589-021-00878-4. Epub 2021 Oct 21.
8
Development of BromoTag: A "Bump-and-Hole"-PROTAC System to Induce Potent, Rapid, and Selective Degradation of Tagged Target Proteins.溴结构域蛋白标记物(BromoTag)的开发:一种用于诱导标记靶蛋白高效、快速和选择性降解的“凸起-凹陷”-PROTAC 系统。
J Med Chem. 2021 Oct 28;64(20):15477-15502. doi: 10.1021/acs.jmedchem.1c01532. Epub 2021 Oct 15.
9
Harnessing the E3 Ligase KEAP1 for Targeted Protein Degradation.利用 E3 连接酶 KEAP1 进行靶向蛋白降解。
J Am Chem Soc. 2021 Sep 22;143(37):15073-15083. doi: 10.1021/jacs.1c04841. Epub 2021 Sep 14.
10
Selective degradation-inducing probes for studying cereblon (CRBN) biology.用于研究cereblon(CRBN)生物学的选择性降解诱导探针。
RSC Med Chem. 2021 Jul 6;12(8):1381-1390. doi: 10.1039/d0md00382d. eCollection 2021 Aug 18.